<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-04-15">April 15, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Marianne</forename><surname>Pavel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hepatology and Gastroenterology</orgName>
								<address>
									<addrLine>Campus-Virchow-Klinikum</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Henning</forename><surname>Jann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hepatology and Gastroenterology</orgName>
								<address>
									<addrLine>Campus-Virchow-Klinikum</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vikas</forename><surname>Prasad</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Nuclear Medicine</orgName>
								<orgName type="institution">Charité Universitätsmedizin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ignat</forename><surname>Drozdov</surname></persName>
							<affiliation key="aff2">
								<orgName type="laboratory">Wren Laboratories</orgName>
								<address>
									<settlement>Branford</settlement>
									<region>Conn</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Irvin</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
							<affiliation key="aff2">
								<orgName type="laboratory">Wren Laboratories</orgName>
								<address>
									<settlement>Branford</settlement>
									<region>Conn</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><surname>Kidd</surname></persName>
							<affiliation key="aff2">
								<orgName type="laboratory">Wren Laboratories</orgName>
								<address>
									<settlement>Branford</settlement>
									<region>Conn</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pavel</forename><forename type="middle">/</forename><surname>Jann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Prasad</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Drozdov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Modlin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Kidd</surname></persName>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">Wren Laboratories</orgName>
								<address>
									<addrLine>35 NE Industrial Rd Branford</addrLine>
									<postCode>06405</postCode>
									<region>CT</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-04-15">April 15, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">2AF1A9F937C8438E399A78878223A4E8</idno>
					<idno type="DOI">10.1159/000446025</idno>
					<note type="submission">Received: January 11, 2016 Accepted after revision: April 5, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:47+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Biomarker</term>
					<term>Carcinoids</term>
					<term>Chromogranin</term>
					<term>Multianalyte</term>
					<term>Neuroendocrine tumor</term>
					<term>NETest</term>
					<term>Polymerase chain reaction</term>
					<term>Prognostic</term>
					<term>Transcript</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>baseline variable (Cox modeling) associated with PFS was NETest (hazard ratio = 1.022, 95% confidence interval = 1.005-1.04;</s><s>p &lt; 0.012).</s><s>Using Kaplan-Meier analyses, the baseline NETest (&gt;80%) was significantly associated (p = 0.01) with disease progression (median PFS 0.68 vs. 2.78 years with &lt;40% levels).</s><s>The NETest was more informative (96%) than CgA changes ( &gt; 25%) in consistently predicting disease alterations (40%, p &lt; 2 × 10 -5 , χ 2 = 18).</s><s>The NETest had an earlier time point change than imaging (1.02 ± 0.15 years).</s><s>Baseline NETest levels &gt;40% in stable disease were 100% prognostic of disease progression versus CgA (χ 2 = 5, p &lt; 0.03).</s><s>Baseline NETest values &lt;40% accurately (100%) predicted stability over 5 years (p = 0.05, χ 2 = 3.8 vs. CgA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion:</head><p><s>The NETest correlated with a well-differentiated GEP-NET clinical status.</s><s>The NETest has predictive and prognostic utility for GEP-NETs identifying clinically actionable alterations ∼ 1 year before image-based evidence of progression.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Over the last decade, sustainable and demonstrably effective clinical advances in the management of gastroenteropancreatic neuroendocrine tumor (GEP-NET) disease have included a well-defined classification system, introduction of novel therapeutic agents, imaging advances and multidisciplinary strategies to coordinate management <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref> .</s><s>Similarly, an appreciation of the limitations of support for neuroendocrine oncology has escalated attention in what was previously a clinically and scientifically underserved disease process <ref type="bibr">[5]</ref> .</s><s>Despite this, there remain two critical areas that limit advances.</s><s>The first is the relative paucity of knowledge in respect of the molecular and mechanistic basis of the disease <ref type="bibr" target="#b6">[6]</ref> .</s><s>The second is the difficulty in accurately identifying alterations in the disease state from an indolent biology or stability to a progressive or a micrometastatic phenotype.</s></p><p><s>GEP-NET assessment is currently represented by an amalgam of clinical judgment, imaging and, to a lesser extent, biomarker measurement <ref type="bibr" target="#b7">[7]</ref> .</s><s>Irrespective of clinical astuteness, the often indolent nature of the disease, the limitations of imaging and the absence of credible biomarkers hinders the identification of disease evolution and presents a challenging management obstacle.</s><s>Disease progression and recurrence or therapeutic responses are usually defined using a combination of anatomical and functional imaging superimposed upon alterations in symptoms or perturbations in biomarkers <ref type="bibr" target="#b7">[7]</ref> .</s><s>Anatomical imaging using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, however, exhibits welldocumented limitations in NETs <ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref> .</s><s>Functional imaging with somatostatin receptor-based strategies, e.g.</s><s><ref type="bibr">68</ref> Ga-somatostatin analog (SSA) PET/CT, is of value <ref type="bibr" target="#b11">[11]</ref> but resolution sensitivity ( ∼ 5-6 mm) and partial volume effects limit the ability to detect small changes in tumors; the discriminant index of progression is below an effective management threshold <ref type="bibr" target="#b12">[12,</ref><ref type="bibr" target="#b13">13]</ref> .</s><s>FDG-PET, though providing useful predictive clinical information, is not established as an early harbinger of disease progression <ref type="bibr" target="#b15">[14]</ref> .</s><s>Current imaging strategies in NETs therefore remain suboptimal <ref type="bibr" target="#b16">[15,</ref><ref type="bibr" target="#b17">16]</ref> .</s></p><p><s>Although biomarkers are used in conjunction with imaging as accessories for clinical decision-making, 'biochemical' responses are nonconcordant with imagebased assessments <ref type="bibr" target="#b0">[1]</ref> .</s><s>This is particularly disappointing since information is readily accessible from blood or urine without either the complexities and limitations of imaging or the risks of invasive and repetitive tissue sampling <ref type="bibr" target="#b18">[17]</ref> .</s><s>To date, identification of an exemplary biomarker(s) in NET oncology has eluded disease stakeholders because of a reliance on monoanalytes, limitations in technology or a lack of understanding of the molecular basis of the disease.</s><s>Candidates have proven to be insensitive, nonspecific or, if accurate, of perfunctory usage in only one disease (e.g.</s><s>gastrin, insulin) <ref type="bibr" target="#b19">[18]</ref> .</s></p><p><s>Chromogranin A (CgA) represents the best-described biomarker but its limitations in terms of assay reproducibility, sensitivity and specificity have been extensively documented with resultant clinical skepticism as to its utility <ref type="bibr" target="#b20">[19]</ref> .</s><s>Other disciplines of oncology have gravitated to the conclusion that exocytotic or protein products fail to capture the biology of a neoplastic cell and that a dynamic and panoramic view of an evolving neoplasm can best be captured by a multidimensional assessment of the cell's molecular genomic machinery.</s><s>This strategy rejects the concept that a monoanalyte measurement shows accurate biomarkers since its unidimensionality cannot mathematically encompass the diversity of the neoplastic environment.</s><s>Multiple analyte measurements and mathematical algorithmic analyses that accurately capture the magnitude of the biological information <ref type="bibr" target="#b21">[20]</ref> provide the basis for acceptable biomarker strategies <ref type="bibr" target="#b22">[21]</ref> .</s></p><p><s>In GEP-NET disease, circulating tumor cells, micro-RNA levels and circulating transcript analysis have been evaluated.</s><s>The former represents an intriguing nascent technology but current methodological limitations hinder clinical applicability, though considerable potential remains to be assessed pending the development of single cell genomic analysis <ref type="bibr" target="#b23">[22]</ref> .</s><s>MicroRNA measurement is of interest though confounding factors are disease specificity and the immense heterogeneity of the molecules and their proxies <ref type="bibr" target="#b24">[23]</ref> .</s><s>Currently, the most widely investigated biomarker tool is represented by bloodbased multianalyte transcript analysis <ref type="bibr" target="#b25">[24,</ref><ref type="bibr" target="#b26">25]</ref> .</s><s>Blood gene expression closely correlates with tumor tissue expression levels, and inferential gene analysis of relevant clusters captures the biology of neuroendocrine neoplasia facilitating the accurate definition of clinical status <ref type="bibr" target="#b27">[26]</ref> .</s></p><p><s>The multianalyte-derived NET gene signature encompasses the expression of 51 genes assessed by 4 different prediction algorithms.</s><s>This is then scaled to a disease/ tumor activity (0-100%) score <ref type="bibr" target="#b27">[26]</ref> , using expressions that specifically capture the hallmarks of neoplasia <ref type="bibr" target="#b28">[27]</ref> , and may be used to provide direct information about the tumor, its pathophysiology, and its state of evolution from stability to progression.</s><s>To assess this, we prospectively collected blood samples from NET disease patients at a single center (ENETS Center of Excellence -Charité, Berlin) over a ∼ 5-year time period and appraised the utility of biomarkers and imaging in defining the bandwidth of the disease spectrum that embraces that most critical clinical decision-making fulcrum: when stability and disease remission become progression.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Thirty-four GEP-NETs (collected between May and October 2009) were histopathologically confirmed as well differentiated (n = 31; grade 1 or 2), 1 was grade 3, and 2 were not available when studied.</s><s>Patient demographics are summarized in table 1 .</s><s>Thirtyone had radiologically demonstrable disease (stage IV), ascertained within 6 months prior to study initiation; 3 exhibited no evidence of disease.</s><s>All patients provided informed consent for the blood translational analysis authorized by the local ethics committee (authorization EA2_064_09).</s><s>Patients were followed up for a median of 4 years (2.2-5.4 years), and imaging was undertaken as dictated by their clinical condition and response to therapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blood Sampling Schedule</head><p><s>Whole blood (10 ml) for transcript analysis was collected at baseline and thereafter at clinically defined points during the follow-up.</s><s>Plasma for CgA analysis was obtained at exactly the same time points.</s><s>Overall, blood samples were collected a median 2.5 times per patient (range: 2-5).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Image Analysis</head><p><s>Anatomical imaging (CT/MRI) was used to evaluate patients at study entry and at appropriate time intervals until progression occurred.</s><s>RECIST 1.0 criteria were used to assess therapy response.</s><s>The consensus for the therapeutic response as stable disease (including partial response or complete remission, CR) or disease progression during follow-up was confirmed by a NET Tumor Board Group (M.P., H.J., V.P.).</s><s>Staging was undertaken a median 7 times per patient (range: 3-15).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PCR-Based Transcript Analysis NETest</head><p><s>The NETest assesses biological activity using gene inference technology and cancer hallmark prediction <ref type="bibr" target="#b27">[26]</ref> .</s><s>Details of the PCR methodology, mathematical analysis and validation have been published in detail <ref type="bibr" target="#b25">[24,</ref><ref type="bibr" target="#b27">26,</ref><ref type="bibr" target="#b29">28,</ref><ref type="bibr" target="#b30">29]</ref> .</s><s>The procedure utilizes a 2-step protocol (RNA isolation, cDNA production and PCR) <ref type="bibr" target="#b25">[24,</ref><ref type="bibr" target="#b29">28]</ref> from EDTA-collected whole blood <ref type="bibr" target="#b25">[24,</ref><ref type="bibr" target="#b29">28]</ref> .</s><s>The expression of 51 NET marker genes includes analysis of clusters of biologically relevant genes that constitute the different 'omes' (SSTRome, proliferome, metabolome, secretome, epigenome and pluromes) <ref type="bibr" target="#b27">[26]</ref> which define the NET 'fingerprint'.</s><s>Expression was normalized to housekeepers and quantified versus a population control <ref type="bibr" target="#b25">[24]</ref> .</s><s>Multianalyte algorithm analysis was undertaken (support vector machine, linear discriminant analysis, K-nearest neighbor, and Bayes classifier) for categorization into different groups using the 'majority vote' <ref type="bibr" target="#b25">[24]</ref> .</s><s>This results in a 0-8 score <ref type="bibr" target="#b25">[24,</ref><ref type="bibr" target="#b29">28]</ref> which is converted to an activity ranging from 0 (low activity) to 100% (high activity) based on the expression of 'omic' genes <ref type="bibr" target="#b27">[26]</ref> .</s><s>Elevated expression of these genes is used to weight the score such that a high score, e.g.</s><s>'8', when combined with elevated 'omes' (identified to differentiate progressive disease, PD, from stable disease <ref type="bibr" target="#b27">[26]</ref> ) is scaled to 100% (high activity).</s><s>A score of '8' with a low 'ome' is weighted to 53%.</s><s>We determined the ranges that conform to clinical disease assessment: minimal activity = &lt;0-14%, low activity = 14-40%, and intermediate-high activity = &gt;40-100% <ref type="bibr" target="#b27">[26]</ref> .</s><s>In this study, we used ≥ 80% as a cutoff for progressive disease, i.e. a NETest score of 80-100% as indicative of highly active disease.</s><s>This has previously been used as a cutoff to predict disease progres-sion in SSA-treated patients <ref type="bibr" target="#b30">[29]</ref> .</s><s>We also evaluated a lower value ( ≥ 70%) to assess whether this would function as a more effective/ sensitive predictor of disease progression.</s><s>This is based on a preliminary affinity propagation algorithm analysis <ref type="bibr" target="#b31">[30]</ref> undertaken on the sample set that identified a value ≥ 70% to be informative for predicting disease progression.  1 Three patients were not included in the group analysis: 45 years old, F, grade 1, duodenum, surgery (disease-free for entirety of study); 69 years old, M, grade 1, duodenum, surgery (diseasefree for entirety of study); 63 years old, M, grade 3, pancreas, surgery (disease-free at start but recurrence at 2.2 years).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prognostic Utility of the NETest</head><p><s>Neuroendocrinology 2017;104:170-182 DOI: 10.1159/000446025 173 CgA Assay Serum CgA was measured using a competitive radioimmunoassay (CGA-RIACT, Cisbio Bioassays) <ref type="bibr" target="#b32">[31]</ref> .</s><s>This is a solid-phase 2-site immunoradiometric assay; two monoclonal antibodies are used against sterically remote sites on CgA.</s><s>The assay can detect whole and fragmentary CgA species and is a standard assay at the Charité.</s><s>The reference range was 19-150 μg/l; 150 μg/l was used to define the upper limit of normal (ULN).</s><s>Values &gt;150 μg/l signified an elevated CgA, while values ≥ 300 μg/l (2 × ULN) were used to signify abnormally elevated CgA <ref type="bibr" target="#b33">[32]</ref> .</s><s>In subjects with elevated CgA, an increase ≥ 25% between any two time points was used as a measure to predict disease progression.</s><s>This is based on a previous retrospective study which found that this value exhibited a sensitivity and specificity of &gt;85% for predicting disease progression during patient monitoring <ref type="bibr" target="#b34">[33]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Grading</head><p><s>Tumors were graded (1, 2, or 3) according to the WHO classification, utilizing the Ki-67 values obtained from the original histopathological reports <ref type="bibr" target="#b35">[34]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analyses</head><p><s>Analyses included χ 2 (Fisher's, 2-tailed), nonparametric (Mann-Whitney, 2-tailed) measurements, Kaplan-Meier survival curves (progression-free survival, PFS), event curve analysis (based on Kaplan-Meier curves), and multivariate analysis (Cox proportional-hazard regression).</s><s>Prism 6.0 for Windows (GraphPad Software, La Jolla Calif., USA; www.graphpad.com)</s><s>and MedCalc Statistical Software version 16.2.1 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org;</s><s>2013) were utilized.</s><s>PFS of the cohort over the extent of the study (i.e.</s><s>time from baseline to image-verified disease progression) was assessed to provide a descriptive overview of the cohort.</s><s>The utility of baseline biomarkers for predicting PFS based on imaging (RECIST) was examined at two different time points (baseline = time 0 and Time 1 = a subsequent follow-up time when the majority of the patients, i.e. n = 29, had blood sample collections).</s><s>For NETest predictive accuracy assessment, cutoffs of 70 and 80% were evaluated.</s><s>CgA levels &gt;150 and ≥ 300 μg/l (2 × ULN) were evaluated.</s><s>For the event curve analyses, the time difference between a blood sample and image-based evidence for disease progression was identified.</s><s>For individual biomarkers, the data are presented as means ± SEM.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Demographics</head><p><s>Thirty-four patients (stable n = 18, 53%; PD n = 9, 26%; disease free on CT/MRI, i.e.</s><s>CR, n = 3, 9%; partial remission n = 1, 3%; disease status not known n = 3, 9%) were included ( table <ref type="table" target="#tab_0">1</ref> ).</s><s>Disease types included small intestine (n = 24), pancreas (n = 7), 2 multiple endocrine neoplasia/ Zollinger-Ellison syndrome and 1 cancer of unknown primary.</s><s>Most cases were TNM stage IV (31/34), and 3 were CR (no evidence of disease on CT/MRI) following (curative) surgery.</s><s>Subjects were a median 57 years old at the time of enrollment (range 43-83 years) with a similar gen-der ratio of M:F 17: 17.</s><s>The WHO grading distribution was grade 1 = 17, grade 2 = 14, grade 3 = 1, while 2 had no grade available.</s><s>Previous therapy included surgery (n = 23), SSAs (n = 9) and streptozotocin/5-fluorouracil (n = 2).</s><s>At enrollment, 16 were receiving SSAs, 1 a combination of SSA and everolimus, 3 streptozotocin/5-fluorouracil and 14 were not being treated.</s><s>Treatment modalities thereafter involved use of everolimus (n = 7), peptide receptor radionuclide therapy (n = 5), temozolomide + capecitabine ( n = 4), streptozotocin/5-fluorouracil (n = 2), sunitinib (n = 1) or telotristat etiprate (n = 1).</s><s>Two patients received surgery; 1 received transarterial embolization.</s><s>These were all undertaken after disease progression had been identified (typically 2-3 years into the study).</s><s>These patients were not excluded from the group analysis because blood samples had already been collected prior to this therapy.</s><s>After a median 4.4-year (range 2.2-5.4)</s><s>observation period, 27 were alive, 5 were lost to follow-up and 2 had died.</s></p><p><s>Two were excluded from group analysis because they had CR and remained thus for the duration of the study (patient 15, with Zollinger-Ellison syndrome/duodenum, &lt;1%, surgery: 4.8 years; patient 21, with duodenum, &lt;1%, surgery: 3.2 years).</s><s>A third patient was also excluded due to CR at the start of the study (patient 26, pancreas, 30%, surgery: 2.2 years before disease recurrence).</s></p><p><s>The median PFS for the patient cohort (n = 31) was 2.59 years.</s><s>Patients with PD (n = 7, PD and mixed progression: n = 2) had a lower median survival, 0.7 years, than those with stable disease (i.e.</s><s>stable disease, partial response and not known; 2.7 years, p = 0.11; fig. <ref type="figure" target="#fig_2">1 a</ref>).</s><s>Grade was not related to PFS.</s><s>Disease site influenced PFS ( fig. <ref type="figure" target="#fig_2">1 b</ref>), with pancreatic tumors exhibiting a PFS of 1.84 years compared to 3.67 years for gastrointestinal NETs (p = 0.27).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Baseline Biomarker Parameters CR Patients (n = 3)</head><p><s>The baseline NETest for the 2 patients who were surgically 'cured' was 27 and 14%, while CgA was 343 and 381 μg/l, respectively.</s><s>Two sequential measurements at 2.6 and 3.9 years (in patient 15) were 33 and 33%; CgA was 95 μg/l.</s><s>For patient 21, the NETest at 3.2 years was 20%, CgA was 248 μg/l.</s><s>The third patient developed recurrence after 2.2 years.</s><s>This was a grade 3 (Ki-67 = 30%) pancreatic NET.</s><s>The NETest was 14% at baseline, and the CgA level was 83.1 μg/l.</s><s>The subsequent NETest level was 66.7% when disease recurrence was noted.</s><s>CgA was normal (95 μg/l).</s><s>An additional measurement was lower (NETest 40%; CgA 124 μg/l) when the disease was adequately treated with temozolomide + capecitabine (RECIST -stable).</s></p><p><s>Total CgA Levels (n = 34) At baseline, CgA was 2,261 ± 1,720 μg/l.</s><s>Levels were higher in pancreatic NETs (9,935 ± 8,160 μg/l) than gut NETs (313 ± 77 μg/l, p &lt; 0.006), were increased in grade 2 versus grade 1 (4,767 ± 4,144 vs. 591 ± 378 μg/l, p &lt; 0.05) but were not different by stage (stage IV vs. CR: 2,617 ± 2,014 vs. 495 ± 184 μg/l, p = n.s.).</s></p><p><s>CgA Levels in the Patient Cohort (n = 31) Levels tended to be higher in PD (6,989 ± 6,454 vs. 603 ± 315 μg/l, p = 0.12, fig. <ref type="figure" target="#fig_1">2 a</ref>).</s><s>Sixteen (50%) exhibited elevated (above the ULN = 150 μg/l) CgA levels.</s><s>Twelve of the 16 (75%) had a baseline CgA ≥ 300 μg/l.</s><s>Elevated CgA was not associated (p = 0.26) with the eventual development of progressive disease compared to normal levels ( fig. <ref type="figure" target="#fig_3">3 a</ref>).</s><s>Abnormally high CgA ( ≥ 300 μg/l) was not associated with outcome either, although a shorter median survival was noted (1.24 vs. 2.76 years).</s></p><p><s>Total NETest (n = 34) At baseline, the NETest was 48.4 ± 5%.</s><s>Levels were not different between sites (pancreatic NETs: 57.8 ± 7.3% vs. gut NETs: 42.7 ± 5.9%, p = 0.28) or grade (grade 1: 45.3 ± 7% vs. grade 2: 47 ± 7%, p = n.s.) but were different by stage (stage IV vs. CR: 48.7 ± 5 vs. 16 ± 6%, p = 0.05).</s><s>CgA levels tended (p = 0.12) to be higher in the PD group at baseline.</s><s>Means ± SEM. b NETest levels were significantly elevated in the PD group at baseline (p &lt; 0.05).</s><s>Means ± SEM.</s><s>NETest in the Patient Cohort (n = 31) At baseline, the NETest was 51 ± 5%.</s><s>Levels were significantly higher in the PD group (67.2 ± 7.1 vs. 41.6 ± 5.8%, p &lt; 0.05; fig. <ref type="figure" target="#fig_1">2 b</ref>).</s><s>An elevated NETest (defined as ≥ 80%) was significantly associated (p = 0.014) with the development of PD compared to lower NETest values ( fig. <ref type="figure" target="#fig_3">3 b</ref>).</s><s>The median survival was 0.68 years (NETest ≥ 80%) compared to 2.78 years.</s></p><p><s>Analysis of the 7 patients (clinically stable at baseline) who had an intermediate or high NETest (&gt;40%) identified that all 7 (100%) developed PD in a mean of 24 months (range: 3.6-57.5).</s><s>Conversely, the 7 with stable disease, who never developed disease progression during the duration of the follow-up, all exhibited a low-activity ( ≤ 40%) baseline NETest (mean follow-up: 52 months, range: 32-60.5 months).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Predictive Utility of Biomarkers (n = 31)</head><p><s>The study design allowed us to examine the predictive utility of the NETest compared to CgA at defined, clinically chosen, image-based follow-up times using multivariate and Kaplan-Meier analyses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Multivariate Analysis</head><p><s>We initially investigated which baseline variables were associated with PFS.</s><s>Cox proportional-hazard regression was fitted to the baseline data.</s><s>Baseline CgA (μg/l) and NETest (%) levels as well as histological grade (grade 1 vs. 2) and site (gut vs. pancreas) were evaluated.</s><s>The only significant covariate in the model was the NETest (hazard ratio, HR = 1.022, 95% confidence interval, CI = 1.005-1.04,</s><s>p &lt; 0.012).</s><s>Neither grade (grade 1 vs. 2; HR = 1.095, 95% CI = 0.473-2.54,</s><s>p = 0.83) nor site (HR = 0.72, 95% CI = 0.239-2.17,</s><s>p = 0.56) or CgA (HR = 1.00, 95% CI = 1.00-1.00,</s><s>p = 0.89) were predictive of PFS in this cohort.</s></p><p><s>Kaplan-Meier Analyses (T0 to First Restaging) The mean follow-up time from baseline to the first restaging scan was 194 days (range: 72-422).</s><s>Assessments included: histological grade, NETest ( ≥ 80%), normal versus elevated ( ≥ 150 μg/l, n = 16) and abnormally elevated CgA ( ≥ 300 μg/l, n = 12).</s><s>Values were assessed to predict disease progression at the initial restaging.</s><s>CgA was not informative.</s><s>The median survival with CgA ≥ 150 μg/l was 335 days (vs.</s><s>undefined for normal levels; fig. <ref type="figure" target="#fig_4">4 a</ref>), while it was 247 days in the 12 with CgA ≥ 300 μg/l ( fig. <ref type="figure" target="#fig_4">4 b</ref>).</s><s>The only predictive biomarker was the NETest which exhibited a trend toward significance (p = 0.07) with outcome at this time point ( fig. <ref type="figure" target="#fig_4">4 c, d</ref>).</s><s>The HR for an elevated NETest was 3.3 (95% CI = 0.78-14.3).</s><s>The median survival was 247 days (not reached for NETest ≤ 79%) after 422 days ( fig. <ref type="figure" target="#fig_4">4 c</ref>).</s><s>Lowering the NETest cutoff to 70% improved the HR to 3.5 (95% CI = 0.87-14.0).</s><s>The median survival remained 247 days ( fig. <ref type="figure" target="#fig_4">4 d</ref>).</s></p><p><s>During the follow-up, 29 patients had a second blood sample (both NETest and CgA) and thereafter imagebased restaging.</s><s>The mean time between blood measurement (T1) and restaging was 183 days (range: 26-814).</s><s>CgA was not informative when either assessed in the entire cohort (normal levels vs. elevated levels, fig. <ref type="figure" target="#fig_5">5</ref>  dian survival not reached in either cohort) or using 300 μg/l ( fig. <ref type="figure" target="#fig_5">5 b</ref>).</s><s>In the latter, the median survival with an elevated CgA was undefined.</s><s>Assessment of the NETest (using cutoffs of ≥ 70 or ≥ 80%) found that this was predictive ( fig. <ref type="figure" target="#fig_5">5 c, d</ref>).</s><s>The HR for the NETest ( ≥ 80%) was 5.5 (95% CI = 0.77-38.9)</s><s>with a median survival of 246 days (vs.</s><s>not reached, p = 0.07; fig. <ref type="figure" target="#fig_5">5 c</ref>).</s><s>Using a cutoff of 70%, the HR was 23.5 (95% CI = 4.7-116.5),</s><s>and the median survival was 183 days (not reached for NETest ≤ 69%, p = 0.0009; fig. <ref type="figure" target="#fig_5">5 d</ref>).</s></p><p><s>The NETest was more informative than elevations in CgA.</s><s>NETest alterations (a rise to ≥ 80% in progressive disease or remaining low ( ≤ 40%) in stable disease) occurred more consistently (24/25, i.e. 96%) than alterations in CgA (e.g.</s><s>elevation ≥ 25% or no change in SD: 10/25, i.e. 40%, p &lt; 2 × 10 -5 , χ 2 = 18.1).</s><s>The time point at which the NETest ( ≥ 80%) was measured prior to image evidence of PD was significantly earlier (1.02 ± 0.15 years) than for alterations in CgA (Δ25%: 0.51 ± 0.11 years, p = 0.034).</s><s>Elevated CgA ( ≥ 300 μg/l) occurred at 0.52 ± 0.13 years before indication of disease (p = n.s. vs. CgA Δ25%).</s><s>If a NETest ≥ 70% was used, the time point was even earlier.</s><s>Progression was predicted 1.85 ± 0.27 years prior to image confirmation.</s><s>This was significantly earlier than for either NETest ( ≥ 80%, p &lt; 0.02) or for CgA (Δ25%, p = 0.003).</s><s>Event curves for each of the biomarkers ( fig. <ref type="figure" target="#fig_6">6 a,  b</ref>) show that the median times prior to image-confirmed disease progression for CgA were 0.51 years (Δ25%) and 0.60 years ( ≥ 300 μg/l), and for the NETest they were 0.76 years ( ≥ 80%) and 1.62 years ( ≥ 70%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>A critical unresolved issue in GEP-NET management is the early identification of disease progression <ref type="bibr" target="#b31">[30]</ref> .</s><s>Effective prognostic biomarkers are not robust, and imaging is relatively insensitive <ref type="bibr" target="#b10">[10,</ref><ref type="bibr" target="#b36">35]</ref> .</s><s>The current consensus is that an accurate circulating biomarker that captures the biological activity of a NET and predicts its clinical behavior would provide an optimal method for the early detection of disease progression <ref type="bibr" target="#b0">[1]</ref> .</s><s>We evaluated the role of a blood-based multigene transcript analysis as such a predictive and prognostic marker and assessed whether the performance was more effective than standard biomarkers providing added clinical utility.</s></p><p><s>RECIST criteria are the current default for defining therapeutic responses although their limitations are well documented <ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref> .</s><s>Local confounders such as necrosis, hemorrhaging or fibrosis complicate assessment <ref type="bibr" target="#b37">[36]</ref> while the spatial resolution of CT/MRI ( ∼ 2 mm) approaches the limits of tumor measurement, particularly for recurrent or micrometastatic disease.</s><s>This issue together with observer-dependent accuracy (low kappa) further confounds accuracy.</s><s>Such difficulties are amplified by the often indolent growth rates of well-and moderately differentiated NETs.</s></p><p><s>Biomarkers such as CgA define tumor secretion and do not reflect biological activities including cell proliferation, growth factor signaling or any of the 'hallmarks of cancer' <ref type="bibr" target="#b38">[37]</ref> .</s><s>A variety of metrics have been assessed to evaluate the use of these markers.</s><s>For example, a 30% decrease in CgA (from pretreatment levels) is considered predictive of SSA efficacy <ref type="bibr" target="#b39">[38]</ref> , while an increase in three 178 consecutive measurements is considered to anticipate relapse after midgut surgery <ref type="bibr" target="#b40">[39]</ref> .</s><s>Some authors proposed that alterations of ≥ 25% in CgA may have good sensitivities (&gt;75%) and specificities (&gt;85%) for predicting disease events <ref type="bibr" target="#b34">[33]</ref> while others suggested that levels twice the ULN ( ∼ 300 μg/l or 300 ng/ml) <ref type="bibr" target="#b33">[32]</ref> or higher ( ≥ 600) <ref type="bibr" target="#b41">[40]</ref> are effective predictors of disease progression.</s><s>Irrespective of the cutoff levels proposed, numerous technical issues, e.g.</s><s>low reproducibility and disease confounders (drugs, diseases), limit its utility.</s><s>CgA and other single (mono)analyte biomarkers have not met the expectations of the clinical community <ref type="bibr" target="#b20">[19,</ref><ref type="bibr">41,</ref><ref type="bibr" target="#b44">42]</ref> .</s></p><p><s>Investigation has focused on the development of multianalyte assays that can identify multiple key elements of neoplastic cell function and be interfaced with sophisticated mathematical models (multianalyte algorithm analysis).</s><s>This approach has been acknowledged as necessary to define and predict the exquisite complexity of the neoplastic conundrum <ref type="bibr" target="#b45">[43]</ref> .</s><s>Defining the bandwidth of the genomic regulation of neoplasia requires the simultaneous assessment of numerous parameters that circumscribe diverse aspects of tumor biology and facilitate the 'framing' of clinical behavior <ref type="bibr" target="#b46">[44]</ref><ref type="bibr" target="#b47">[45]</ref><ref type="bibr" target="#b48">[46]</ref> .</s><s>Numerous successful applications of this principle have advanced the disease management of neoplasia in other sites including breast, liver, colon, prostate and lung cancer <ref type="bibr" target="#b46">[44,</ref><ref type="bibr" target="#b49">[47]</ref><ref type="bibr" target="#b50">[48]</ref><ref type="bibr" target="#b51">[49]</ref><ref type="bibr" target="#b52">[50]</ref> .</s></p><p><s>Multianalyte algorithm analysis strategies based upon a 51-gene signature (NETest) have been reported in NETs <ref type="bibr" target="#b25">[24,</ref><ref type="bibr" target="#b27">26,</ref><ref type="bibr" target="#b29">28,</ref><ref type="bibr" target="#b30">29,</ref><ref type="bibr" target="#b53">[51]</ref><ref type="bibr" target="#b54">[52]</ref><ref type="bibr" target="#b55">[53]</ref> .</s><s>This defines the circulating NET 'fingerprint' <ref type="bibr" target="#b56">[54]</ref> and exhibits a higher sensitivity and specificity (98 and 97%, respectively) than secretory markers for identifying neoplasia <ref type="bibr" target="#b26">[25,</ref><ref type="bibr" target="#b53">51]</ref> .</s><s>The assay is standardized and highly reproducible (inter-and intraassay coefficient of variation &lt;2%), and is independent of tumor heterogeneity <ref type="bibr" target="#b29">[28]</ref> .</s><s>Gene expression is captured in a 0-8 score derived from 4 different prediction algorithms that is mathematically scaled to disease activity (0-100%) by interpolating the expression of 'omic' transcripts that define specific biological components (hallmarks) of neoplasia <ref type="bibr" target="#b28">[27]</ref> .</s><s>HR-derived analyses enable the derivation of scores that define disease activity (0-14%, minimal activity; 14-40%, low activity; &gt;40%, intermediate and high activity) <ref type="bibr" target="#b27">[26]</ref> .</s><s>Individual activity levels correlate accurately with clinically stable disease or PD and effectively facilitate the determination of treatment efficacy <ref type="bibr" target="#b27">[26]</ref> .</s></p><p><s>In the current study, all patients were NETest positive, e.g.</s><s>≥ 14% at baseline.</s><s>NETest levels were significantly (p &lt; 0.05) elevated in 8 (90%) of the 9 patients identified with PD.</s><s>One patient (terminal ileum, grade 1) had a score of 20%, and was termed as 'mixed' progression, suggesting the low score reflected a response to therapy (SSA).</s><s>An analysis of the 7 (defined as clinically stable at baseline) who did not have a low tumor activity NETest (i.e.</s><s>scores &gt;40%) showed that all developed PD with a mean of 24 months (range: 3.6-57.5</s><s>months).</s><s>Conversely, 7 stable (at baseline) patients who never developed disease progression exhibited a low-activity (&lt;40%) NETest While this shows some discordance between the NETest and imaging at a particular point in time (50% of patients had low activity, 50% high activity despite all 14 exhibiting disease 'stability'), the NETest accurately (100%) predicted outcome.</s><s>This is predictable given the limitations of imagery in terms of sensitivity and defining biological activity.</s><s>An image cannot intrinsically provide dynamic information about tumor activity whereas a circulating molecular fingerprint that defines neoplastic biology is specifically designed to identify and quantify such information.</s><s>These data suggest that the use of blood-based tumor-derived molecular information in conjunction with standard imaging may provide added clinical value in defining disease status and guiding therapy.</s></p><p><s>Three patients (No. 15, 21, and 26) are worthy of consideration.</s><s>All were surgically cured ('complete resection') at operation.</s><s>They comprised 2 low-grade (Ki-67 &lt;1%) duodenal NETs (one, patient 15, was a gastrinoma) and a pancreatic tumor.</s><s>Two of the 3 'surgically cured' individuals (No. 15 and 21) did not exhibit 'clinical' evidence of disease (by CT/MRI) for the duration of the study.</s><s>Their NETest scores at baseline (after surgery) were 27 and 20%, respectively.</s><s>Two sequential measurements at 2.6 and 3.9 years in patient 15 were 33 and 33%, respectively; for patient 21, the NETest at 3.2 years was 20%.</s><s>These fall into the 'low-activity' range.</s><s>In a separate 5-year follow-up study of a surgical cohort (n = 12; all with NET grade 1, none with gastrinoma), complete resection was associated with NETest levels &lt;14% <ref type="bibr" target="#b54">[52]</ref> .</s><s>The elevated postsurgical level in the duodenal gastrinoma patient (33%) in the current study is of concern and may reflect microscopic disease not identifiable at imaging.</s><s>Low-activity, image-negative disease is suggested by the follow-up circulating values (33%).</s><s>One patient, No. 26, with no disease at baseline, developed recurrence after 2.2 years.</s><s>This was a grade 3 (Ki-67 = 30%) pancreatic NET.</s><s>The NETest was 14% at baseline, and CgA levels were normal.</s><s>Thereafter, NETest levels increased (score &gt;65%) while CgA remained normal.</s><s>The borderline score (14%) after surgery suggests that the completeness of surgical excision might require re-evaluation.</s><s>The subsequent rise demonstrates that the tumor recurred.</s><s>The elevation in the NETest was concordant with disease recurrence and importantly occurred ∼ 6 months before any measureable elevation in CgA.</s></p><p><s>Cox proportional-hazard modeling identified that of all variables assessed, only the NETest was predictive of PFS.</s><s>The HR was 1.022 demonstrating that for each percentage point change (increase) in the NETest, the risk of disease progression was 2.2%.</s><s>NETest values for &gt;70 or &gt;80% would therefore have HRs of ∼ 2.5 and ∼ 2.8, respectively.</s><s>In this model, baseline CgA (HR = 1) and site (HR = 0.72) were not associated with PFS.</s><s>In addition, histological grade was not a significant variable either (HR = 1.095).</s><s>The low numbers (n = 31) likely contribute to the absence of statistical significance; however, despite this, the NETest was mathematically identified as being significant even in this cohort.</s></p><p><s>We also performed Kaplan-Meier PFS analysis which identified that the NETest ( ≥ 80 or ≥ 70%) at baseline (T0) exhibited a trend toward significance (p = 0.06) with predicting outcome (RECIST-based assessment after a mean of ∼ 6 months).</s><s>Proof of principle for the NETest as a prognostic was confirmed by clinical assessment after a second blood sample.</s><s>The mean time to the second image assessment was also 6 months.</s><s>In this cohort (n = 29), the NETest ( ≥ 80%) was associated with a median survival of 246 days (vs.</s><s>not reached for NETest ≤ 79%).</s><s>Decreasing the cutoff to 70% resulted in an HR of 25.7 (95% CI = 5.2-129).</s><s>The median survival was 183 days (not reached for NETest ≤ 69%, p &lt; 0.00001).</s><s>These analyses (Cox/ Kaplan-Meier) show that NETest levels are a significant prognostic variable in GEP-NETs (independent of grade and site) and can accurately predict clinical outcome as well as response to therapy.</s></p><p><s>CgA, in contrast to the NETest and consistent with its function as a unidimensional measure of secretion, was not an effective biomarker.</s><s>Firstly, it was not identified in the Cox proportional-hazard model as an informative variable.</s><s>Secondly, elevated levels, i.e. &gt;1 × ULN, were only noted in 50% of patients at baseline, thus half the patients could ab initio derive no value from its assessment.</s><s>This is confirmed by multivariable analysis.</s><s>Moreover, the 2 'surgically cured' patients (no evidence of disease recurrence) had elevated baseline levels, 343 μg/l (patient 15) and 381 μg/l (patient 21), respectively.</s><s>Subsequent measurements showed that CgA was only normalized in patient 21.</s><s>Patient 15, who had a gastrinoma, had elevated levels consistent with the secretory behavior captured by this biomarker.</s><s>Baseline CgA was not statistically significantly elevated in the PD cohort.</s><s>A subanalysis of the 16 with elevated baseline found that abnormally high (2 × ULN) levels ( ≥ 300 μg/l) were not associated with outcome.</s><s>Kaplan-Meier analysis did not identify any significant role for CgA as a prognostic marker in this cohort either.</s><s>Use of higher cutoffs, e.g.</s><s>≥ 600 μg/l, was also noninformative.</s></p><p><s>In head-to-head comparisons, the NETest was significantly more informative than alterations in CgA.</s><s>Assessment of NETest alterations (elevation to levels ≥ 80% in PD or remaining low, i.e. &lt;47%, in stable disease) oc-curred more consistently (96%) than alterations in CgA (e.g.</s><s>elevation ≥ 25%, p &lt; 2 × 10 -5 ).</s><s>This should be considered in the context that in 50% of patients, CgA was never elevated despite a histological NET diagnosis.</s><s>Of considerable relevance was the observation that elevations in NETest ( ≥ 80%) occurred at a significantly earlier time point than image evidence of PD.</s><s>Such changes occurred ∼ 1 ± 0.15 years before image confirmation of disease, time points similar to that identified for circulating DNA in colorectal cancer (mean = 10 months) <ref type="bibr" target="#b57">[55]</ref> .</s><s>More germane to the early identification of disease progress was the observation that if the cutoff was adjusted downward to ≥ 70%, the time point of identification of disease progression was significantly earlier.</s><s>A NET level of ≥ 70% enabled identification of disease progression ∼ 2 years prior to evidence of image-identifiable disease progression.</s><s>This was significantly earlier than for a ≥ 80% cutoff (p &lt; 0.02).</s><s>In contrast, alterations in CgA were less informative.</s><s>A change of 25% or any elevation ≥ 300 μg/l occurred only ∼ 0.5 years prior to image-based confirmation and was unidentifiable in 50%.</s></p><p><s>These data are consistent with the proposal that the NETest had a prognostic role in this cohort and confirms utility in clinical management as has been previously noted <ref type="bibr" target="#b30">[29]</ref> .</s><s>High levels are associated with disease progression while low levels reflect and predict disease stability.</s><s>Limitations of the study include the relatively small numbers (34 patients, the final analyzed cohort included 31 patients), that this was not a formal prospective study in a homogenously treated cohort (blood sampling was undertaken on average 2.5/patient and restaging on average ∼ 7 occasions/patient) and that some of the data were extracted and confirmed retrospectively (e.g.</s><s>imaging was re-evaluated according to RECIST, some CgA samples were measured retrospectively).</s><s>The study strengths in-clude that it was undertaken at an ENETS Center of Excellence (Charité, Berlin) in a 'real-world' setting with state-of-the-art imaging (single center), follow-up and patient care using standardized biomarker assessments.</s><s>The concordance in the results between two different statistical approaches, Cox proportional-hazard regression and Kaplan-Meier assessment, substantiate the utility of the NETest as a biomarker.</s><s>The data further define the increasing awareness of the limitations of CgA measurements.</s></p><p><s>In conclusion, the NETest is an independent variable predictive of clinical disease status.</s><s>The measurement of this circulating transcript signature correlates with clinical disease status, and levels ( ≥ 70%) are prognostic for welldifferentiated GEP-NET progression (per RECIST).</s><s>The NETest &lt;40% correlated with disease stability over ∼ 5 years, identifying this molecular signature also as predictive.</s><s>Patients clinically categorized as stable with high NETest levels ( &gt; 70%) develop disease progression in 100% of cases within 2 years.</s><s>The overall utility is emphasized by observations that clinically actionable alterations occurred ∼ 1 year before image-based evidence of disease progression.</s><s>Unlike single analyte secretory measurements, the NETest accurately defines the spectrum of well-differentiated GEP-NET disease and, more critically, can predict when disease stability evolves into progression.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Figures in parentheses indicateranges.</s><s>CR = Complete remission; T0 = time of first blood sample; STZ = streptozotocin; 5-FU = 5-fluorouracil; PRRT = peptide receptor radionuclide therapy; TEMCAP = temozolomide + capecitabine; TAE = transarterial embolization.1 Three patients were not included in the group analysis: 45 years old, F, grade 1, duodenum, surgery (disease-free for entirety of study); 69 years old, M, grade 1, duodenum, surgery (diseasefree for entirety of study); 63 years old, M, grade 3, pancreas, surgery (disease-free at start but recurrence at 2.2 years).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. Baseline blood-based biomarker expression (n = 31).</s><s>a Groups had PD at baseline (n = 9) or stable disease (SD; n = 22).CgA levels tended (p = 0.12) to be higher in the PD group at baseline.</s><s>Means ± SEM. b NETest levels were significantly elevated in the PD group at baseline (p &lt; 0.05).</s><s>Means ± SEM.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>PFS in the cohort (n = 31).</s><s>a Groups defined by imaging had PD at baseline (n = 9) compared to those with stable disease (SD) or identified as partial response (PR) to therapy.</s><s>The 3 patients who were undefined (not known: NK) were included in the stable disease group.</s><s>The median PFS was 0.7 years in the PD group versus 2.71 years (p = 0.11).</s><s>b PFS assessed by tumor site.</s><s>Pancreatic NETs had a PFS of 1.84 years compared to gastrointestinal (GI) tract tumors with 3.70 years (p = 0.27).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. Relationship between survival and baseline biomarker levels.</s><s>a PFS was not associated with baseline CgA in this cohort; normal CgA levels ( ≤ 150 μg/l) were associated with a median survival of 2.65 years compared to 2.43 years in those with elevated (&gt;150 μg/l) levels (p = 0.26).</s><s>b NETest activity at baseline (&lt;80%) was associated with PFS of 2.78 years versus 0.68 years (p &lt; 0.02) in those with &gt;80%.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 4 .</head><label>4</label><figDesc><div><p><s>Fig. 4. Blood-based biomarkers and relationship with survival (baseline time point: T0, n = 31) assessed using Kaplan-Meier analysis.</s><s>a PFS was not associated with elevated (&gt;150 μg/l) CgA levels.</s><s>b PFS was not linked to abnormally elevated CgA ( ≥ 300 μg/l) at baseline in the 12 patients with elevated CgA.</s><s>c PFS was associated with baseline NETest activity in this cohort; the median survival was 247 days in those with NETest &gt;80% (p = 0.07).</s><s>d PFS was associated with baseline NETest activity in this cohort; the median survival was 247 days in those with NETest &gt;70% (p = 0.06).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Fig. 5 .</head><label>5</label><figDesc><div><p><s>Fig. 5. Blood-based biomarkers and relationship with survival (second blood time point: T1, n = 28) assessed using Kaplan-Meier analysis.</s><s>a PFS was not associated with elevated (&gt;150 μg/l) CgA levels.</s><s>b PFS was not linked to abnormally elevated CgA ( ≥ 300 μg/l) at the second blood time point (T1).</s><s>c , d PFS was associated with baseline NETest activity in this cohort; the median survival was 246 days (cutoff &gt;80%) or 183 days (cutoff &gt;70%).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Fig. 6 .</head><label>6</label><figDesc><div><p><s>Fig.6.</s><s>Time before blood-based biomarker elevations preceded image-based evidence for PD. a Changes in CgA (ΔCgA, &gt;25%) occurred at a time point (0.51 years) similar to an elevated CgA ( ≥ 300 μg/l: 0.60 years) prior to image-detected disease progression.</s><s>Only 50% of patients (16 of 32) exhibited elevated CgA at baseline with a subset of 10 exhibiting abnormally elevated ( ≥ 300 μg/l) CgA.</s><s>b The median times prior to image-confirmed disease progression for the NETest were 0.76 years (&gt;80%) and 1.62 years (&gt;70%).</s><s>All patients were NETest positive (&gt;14%).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Patient demographics</s></p></div></figDesc><table><row><cell>Characteristic</cell><cell>Entire cohort (n = 34)</cell></row><row><cell>Mean age, years</cell><cell>60.2 (43 -83)</cell></row><row><cell>Gender (M:F)</cell><cell>17:17</cell></row><row><cell>Grade</cell><cell></cell></row><row><cell>1</cell><cell>1 7</cell></row><row><cell>2</cell><cell>1 4</cell></row><row><cell>3</cell><cell>1</cell></row><row><cell>Unknown</cell><cell>2</cell></row><row><cell>Site</cell><cell></cell></row><row><cell>Gut</cell><cell>25</cell></row><row><cell>Pancreas</cell><cell>9</cell></row><row><cell>Stage</cell><cell></cell></row><row><cell>CR 1</cell><cell>3</cell></row><row><cell>Stage IV</cell><cell>31</cell></row><row><cell>Status</cell><cell></cell></row><row><cell>Stable</cell><cell>18</cell></row><row><cell>Progressive</cell><cell>9</cell></row><row><cell>Disease free</cell><cell>3</cell></row><row><cell>Partial remission</cell><cell>1</cell></row><row><cell>Disease status not known</cell><cell>3</cell></row><row><cell>Treatment at T0</cell><cell></cell></row><row><cell>None</cell><cell>14</cell></row><row><cell>SSA</cell><cell>16</cell></row><row><cell>SSA + everolimus</cell><cell>1</cell></row><row><cell>STZ/5-FU</cell><cell>3</cell></row><row><cell>Treatment during study</cell><cell></cell></row><row><cell>Everolimus</cell><cell>7</cell></row><row><cell>PRRT</cell><cell>5</cell></row><row><cell>TEMCAP</cell><cell>4</cell></row><row><cell>STZ/5-FU</cell><cell>2</cell></row><row><cell>Surgery</cell><cell>2</cell></row><row><cell>Sunitinib</cell><cell>1</cell></row><row><cell>Telotristat etiprate</cell><cell>1</cell></row><row><cell>TAE</cell><cell>1</cell></row><row><cell>Median baseline CgA, μg/l</cell><cell>157 (67 -58,600)</cell></row><row><cell>Median baseline NETest, %</cell><cell>40 (6.7 -93.4)</cell></row><row><cell>Figures in parentheses indicate</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Neuroendocrinology 2017;104:170-182 DOI: 10.1159/000446025</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We thank Ines Eichorn for sample acquisition.</s><s>The study was supported by Clifton Life Sciences.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure Statement</head><p><s>There is no conflict of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Biomarkers for neuroendocrine tumor disease: a delphic consensus assessment of multianalytes, genomics, circulating cells and monoanalytes</title>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Deherder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Klimstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Frilling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Heaney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kwekkeboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Strosberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Washington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wolin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Goldenring</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">e435046</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">F</forename><surname>Pape</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Perren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Niederle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gress</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Denecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Plockinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Salazar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grossman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="135" to="156" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Couvelard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Krenning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Steinmuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Anlauf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wiedenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Salazar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="157" to="176" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Working Group on Neuroendocrine Liver Metastases: Recommendations for management of patients with neuroendocrine liver metastases</title>
		<author>
			<persName><forename type="first">A</forename><surname>Frilling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Breitenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Salem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kwekkeboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W-Y</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Klersy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Vilgrain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Siegler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Caplin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Solcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Schilsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="e8" to="e21" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
		<idno type="DOI">10.1159/000446025</idno>
	</analytic>
	<monogr>
		<title level="j">Prognostic Utility of the NETest Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="170" to="182" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Snyderwine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="1282" to="1289" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Molecular pathology and genetics of gastrointestinal neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Endocrinol Diabetes Obes</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">4</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Evaluating neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art</title>
		<author>
			<persName><forename type="first">L</forename><surname>De Mestier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dromain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Assignies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Scoazec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lassau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lebtahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Brixi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mitry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Guimbaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Courbon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Herbomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cadiot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="R105" to="R120" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eisenhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Therasse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bogaerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sargent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dancey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arbuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gwyther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mooney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rubinstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shankar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dodd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lacombe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Verweij</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="228" to="247" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Can imaging patterns of neuroendocrine hepatic metastases predict response yttrium-90 radioembolotherapy?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Neperud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mahvash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Garg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Murthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Szklaruk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Radiol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="241" to="247" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">T</forename><surname>Denecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Baur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ihm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">G</forename><surname>Steffen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Arsenic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pascher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wiedenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Radiol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="e550" to="555" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">C</forename><surname>Toumpanakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rinke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Bergestuen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thirlwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Salazar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">21</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Quantification in (68)Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide positron emission tomography/computed tomography: can we be impartial about partial volume effects</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ruf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schiefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kropf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Furth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ulrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kosiek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Denecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pascher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wiedenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Amthauer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="369" to="374" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<author>
			<persName><forename type="first">I</forename><surname>Virgolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bomanji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fanti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Papathanasiou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pepe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Oyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Cristoforo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chiti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<title level="m">Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides</title>
				<meeting>edure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides</meeting>
		<imprint>
			<biblScope unit="page">68</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">-Dota-Toc</forename><surname>Ga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ga-Dota-Noc</forename><surname>Ga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">-Dota-Tate</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2004" to="2010" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">18 F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">T</forename><surname>Binderup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Knigge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Loft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Federspiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kjaer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="978" to="985" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Castano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Maecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Villabona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vazquez-Albertino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Navarro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Metastasis Rev</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">5</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib</title>
		<author>
			<persName><forename type="first">S</forename><surname>Faivre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ronot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dreyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Serrate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hentic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bouattour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Couvelard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Vilgrain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Raymond</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Target Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="127" to="133" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Biomarkers on a roll</title>
	</analytic>
	<monogr>
		<title level="j">Nat Biotechnol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page">431</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Neuroendocrine tumor biomarkers: current status and perspectives</title>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bodei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="265" to="277" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Limitations of chromogranin A in clinical practice</title>
		<author>
			<persName><forename type="first">V</forename><surname>Marotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Nuzzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ferrara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zuccoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Masone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Nocerino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Prete</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Marciello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ramundo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lombardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vitale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Colao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Faggiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomarkers</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="186" to="191" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Characterizing multi-omic data in systems biology</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Exp Med Biol</title>
		<imprint>
			<biblScope unit="volume">799</biblScope>
			<biblScope unit="page" from="15" to="38" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Algorithm development for diagnostic biomarker assays</title>
		<author>
			<persName><forename type="first">R</forename><surname>Izmailov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Guest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Schwarz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Rev Neurobiol</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="279" to="298" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Dive C: Tumorigenicity and genetic profiling of circulating tumor cells in smallcell lung cancer</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Hodgkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Morrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Metcalf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Rothwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Trapani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Polanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Burt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Simpson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Pepper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nonaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Greystoke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Krebs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Antonello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ayub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Faulkner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Priest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Blackhall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Brady</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="897" to="903" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Essaghir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Martijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Demoulin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Giandomenico</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod Pathol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="685" to="696" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood</title>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e63364</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">A multianalyte PCR blood test outperforms single analyte ELISAs for neuroendocrine tumor detection</title>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Alaimo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Callahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bodei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="615" to="628" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="561" to="575" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment</title>
		<author>
			<persName><forename type="first">A</forename><surname>Walenkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Crespo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fierro</forename><surname>Maya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fossmark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Igaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rinke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tamagno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vitale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="R445" to="R460" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility</title>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="419" to="429" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Cwikla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bodei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kolasinska-Cwikla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sankowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="E1437" to="E1445" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Clustering by passing messages between data points</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Frey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dueck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="page" from="972" to="976" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Dilz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Denecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">G</forename><surname>Steffen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Prasad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Von Weikersthal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">F</forename><surname>Pape</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wiedenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1253" to="1262" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ter-Minassian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Hooshmand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Brais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Daskalova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Heafield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Buchanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">R</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Fuchs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Christiani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Kulke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="187" to="196" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hilsted</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mynster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Rehfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Knigge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="70" to="77" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Bosman</surname></persName>
		</author>
		<title level="m">WHO Classification of Tumours of the Digestive System</title>
				<imprint>
			<publisher>Lyon, IARC Press</publisher>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Baur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Prasad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Denecke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Radiol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="260" to="270" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever</title>
		<author>
			<persName><forename type="first">L</forename><surname>Bodei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Prasad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="2189" to="2193" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Hallmarks of cancer: the next generation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hanahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Weinberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="646" to="674" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Peracchi M: Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors</title>
		<author>
			<persName><forename type="first">S</forename><surname>Massironi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Conte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sciola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Spampatti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ciafardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Valenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Rossi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="2072" to="2078" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution</title>
		<author>
			<persName><forename type="first">S</forename><surname>Massironi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Casazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Conte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ciafardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Galeazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peracchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="240" to="249" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Ezziddin S: Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sabet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dautzenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Haslerud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Aouf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sabet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Biersack</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1238" to="1246" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Pavel/Jann/</forename><surname>Prasad/Drozdov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">/</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">/</forename><surname>Kidd</surname></persName>
		</author>
		<idno type="DOI">10.1159/000446025</idno>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="170" to="182" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Limitations of chromogranin A in clinical practice</title>
		<author>
			<persName><forename type="first">V</forename><surname>Marotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Nuzzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ferrara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zuccoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Masone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Nocerino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Prete</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Marciello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ramundo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lombardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vitale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Colao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Faggiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomarkers</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="186" to="191" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Kulke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Siu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Tepper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Haller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Benedetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Bergsland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Hobday</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Cutsem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pingpank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Posner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="934" to="943" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Principles and methods of integrative genomic analyses in cancer</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">N</forename><surname>Kristensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">C</forename><surname>Lingjaerde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Russnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Vollan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Frigessi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Borresen-Dale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="299" to="313" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2-early breast cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Exner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Bago-Horvath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bartsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mittlboeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Retel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fitzal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rudas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Singer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pfeiler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gnant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jakesz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dubsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="837" to="842" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">A blood-based biomarker panel for stratifying current risk for colorectal cancer</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mohr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Khettabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nossova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Liew</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="1177" to="1186" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Noninvasive assessment of liver fibrosis in adult patients following the Fontan procedure</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ginde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Hohenwalter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Foley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sowinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Bartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Venkatapuram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Weinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Tweddell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Earing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Congenit Heart Dis</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="235" to="242" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Metagenes associated with survival in non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">E</forename><surname>Urgard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vooder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Vosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Valk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hoti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Roosipuu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Annilo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Laine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Frenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Metspalu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Inform</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="175" to="183" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Zeuzem S: Fibrosure and fibroscan in relation to treatment response in chronic hepatitis C virus</title>
		<author>
			<persName><forename type="first">K</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Friedrich-Rust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lurie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grigorescu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stanciu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Schiff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Haussinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Manns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gerken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Colle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Torbenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pulkstenis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Subramanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Mchutchison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="4581" to="4589" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value</title>
		<author>
			<persName><forename type="first">L</forename><surname>Marisa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>De Reynies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Duval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Selves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Gaub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vescovo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Etienne-Grimaldi</forename><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schiappa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Guenot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ayadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kirzin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chazal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Flejou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Benchimol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lagarde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pencreach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Piard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Elias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Parc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Olschwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Milano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Laurent-Puig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Boige</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e1001453</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Danila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Anand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Heller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Khanin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fleisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lilja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Scher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1191" to="1197" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Aslanian H: The clinical utility of a novel bloodbased multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bodei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="1223" to="1232" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Blood measurement of neuroendocrine gene transcripts defines the effectiveness of surgical resection and ablation strategies</title>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Frilling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Salem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Alaimo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Drymousis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Callahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Faiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bodei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surgery</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="336" to="347" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Gene transcript analysis blood values correlate with (68)Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status</title>
		<author>
			<persName><forename type="first">L</forename><surname>Bodei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Prasad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Severi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kwekkeboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Krenning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Paganelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1341" to="1352" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress</title>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">A4137</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery</title>
		<author>
			<persName><forename type="first">T</forename><surname>Reinert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Scholer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Thomsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tobiasen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nordentoft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lamy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Kannerup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">V</forename><surname>Mortensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stribolt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hamilton-Dutoit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Laurberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pallisgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Orntoft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Andersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="625" to="634" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
